-
11.发明授权公开(公告)号：US08334273B2
公开(公告)日：2012-12-18
申请号：US12970673
申请日：2010-12-16
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521 , C12Y304/21021
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
摘要翻译： 本发明涉及用于抑制因子VII基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US08273869B2
公开(公告)日：2012-09-25
申请号：US12816207
申请日：2010-06-15
申请人： Kevin Fitzgerald , Gregory Hinkle , Akin Akinc , Stuart Milstein
发明人： Kevin Fitzgerald , Gregory Hinkle , Akin Akinc , Stuart Milstein
CPC分类号： A61K31/713 , A61K9/0019 , A61K9/1272 , A61K9/1273 , A61K38/1709 , A61K47/545 , A61K47/55 , A61K47/6911 , C12N15/1137 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515
摘要： This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.
摘要翻译： 本发明涉及使用针对PCSK9基因的脂质配制的siRNA的组合物和方法。
-
13.发明申请公开(公告)号：US20120016009A1
公开(公告)日：2012-01-19
申请号：US13245730
申请日：2011-09-26
IPC分类号： A61K31/713 , A61P9/10 , A61P3/06
CPC分类号： C12N15/87 , A61K48/00 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2320/35 , C12N2310/3521 , C12N2310/3533
摘要： This invention relates to optimized methods for treating diseases caused by PCSK9 gene expression.
摘要翻译： 本发明涉及治疗由PCSK9基因表达引起的疾病的优化方法。
-
公开(公告)号：US20110230542A1
公开(公告)日：2011-09-22
申请号：US12554231
申请日：2009-09-04
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
IPC分类号： A61K31/713 , C12N5/00 , C07H21/02 , A61P3/06
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and
摘要翻译： 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 并且其与PCSK9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由PCSK9基因表达引起的疾病和PCSK9基因表达的方法; 和
-
公开(公告)号：US20110045473A1
公开(公告)日：2011-02-24
申请号：US12811511
申请日：2008-12-31
CPC分类号： G01N33/86 , C12N15/111 , C12N15/1137 , C12N2310/14 , C12Y304/21021 , G01N2333/96447 , Y10T436/143333
摘要： The invention features a method of identifying therapeutically relevant compositions that include a therapeutic agent and a delivery component by screening for an effect of the agent on the liver of a model subject.
摘要翻译： 本发明的特征在于通过筛选试剂对模型受试者的肝脏的影响来鉴定包括治疗剂和递送组分的治疗相关组合物的方法。
-
16.发明授权公开(公告)号：US07871985B2
公开(公告)日：2011-01-18
申请号：US12331708
申请日：2008-12-10
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521 , C12Y304/21021
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
摘要翻译： 本发明涉及用于抑制因子VII基因表达的双链核糖核酸（dsRNA）。
-
17.发明申请公开(公告)号：US20090264511A1
公开(公告)日：2009-10-22
申请号：US12331708
申请日：2008-12-10
IPC分类号： A61K31/7088 , C07H21/02 , C12N5/00 , C12N15/00 , C12N15/63
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521 , C12Y304/21021
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
摘要翻译： 本发明涉及用于抑制因子VII基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US09012498B2
公开(公告)日：2015-04-21
申请号：US13153200
申请日：2011-06-03
申请人： Muthiah Manoharan , Martin Maier , Muthusamy Jayaraman , Shigeo Matsuda , Narayanannair K. Jayaprakash , Kallanthottathil G. Rajeev , Akin Akinc , Thomas A. Baillie
发明人： Muthiah Manoharan , Martin Maier , Muthusamy Jayaraman , Shigeo Matsuda , Narayanannair K. Jayaprakash , Kallanthottathil G. Rajeev , Akin Akinc , Thomas A. Baillie
IPC分类号： A61K31/265 , A61K31/13 , C07C229/00 , C07C229/12 , C12N15/88
CPC分类号： C07C229/12 , A61K31/713 , A61K39/0005 , A61K47/44 , C12N15/113 , C12N15/88 , C12N2310/14 , C12N2320/30
摘要： The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
摘要翻译： 本发明涉及一种阳离子脂质，其具有位于阳离子脂质的脂质部分（例如，疏水链）的中间或远端部分中的一个或多个可生物降解基团。 这些阳离子脂质可以掺入用于递送活性剂（例如核酸）的脂质颗粒中。 本发明还涉及包含中性脂质，能够减少聚集的脂质，本发明的阳离子脂质和任选的固醇的脂质颗粒。 脂质颗粒可以进一步包括治疗剂如核酸。
-
公开(公告)号：US08802644B2
公开(公告)日：2014-08-12
申请号：US13357856
申请日：2012-01-25
申请人： Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
发明人： Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号： C12N15/113 , C07C229/06 , A61K47/12 , A61K47/14
CPC分类号： A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要： The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译： 本发明的特征在于式I的阳离子脂质，包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号：US20130331430A1
公开(公告)日：2013-12-12
申请号：US13472438
申请日：2012-05-15
申请人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
发明人： Pamela Tan , Birgit Bramlage , Maria Frank-Kamenetsky , Kevin Fitzgerald , Akin Akinc , Victor E. Kotelianski
IPC分类号： C12N15/113
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and
摘要翻译： 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 并且其与PCSK9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由PCSK9基因表达引起的疾病和PCSK9基因表达的方法; 和
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.058 秒)
